Consistently, we found that DOT1L inhibition reduced H3K79me2 levels (Supplementary Fig. 2a) and blocked MV411 and Molm14 MLL-rearranged leukemia cell growth in a dose-dependent manner but not the growth of human primary melanocytes (HPMs) or melanomas, including UACC62, A375, C021, C052, A04, and B16 (Supplementary Fig. 2b–d). Here, KMT2A is linked to leukemia.